GLOW carries no published list price, so any dollar figure describes a market rather than a catalog entry. The name refers to a fixed-ratio combination of three peptides sold together in one lyophilized vial: GHK-Cu, a copper tripeptide that carries most of the milligram load, alongside much smaller masses of BPC-157 and TB-500. Observed per-vial pricing has generally run from roughly sixty to just under two hundred US dollars, all of it under research-use-only labelling, and the honest headline is that price correlates only loosely with what a given vial actually contains.
GLOW has no published list price; it is a fixed-ratio vial of GHK-Cu at roughly 30 to 70 mg with BPC-157 and TB-500 near 10 mg each, sold research-use-only at an observed range of about $60 to just under $200 per vial.
Three distinct compounds share the vial, and they sit nowhere near equal measure. GHK-Cu is a three-residue copper-binding tripeptide that is comparatively cheap to synthesize at scale, so loading the vial with it produces a large-sounding total milligram figure at a modest price. That is why the number on the label describes content rather than a potency tier, and why it is a poor proxy for where the cost actually sits.
| Component | GHK-Cu | BPC-157 | TB-500 |
|---|---|---|---|
| Typical load | ~30 to 70 mg | ~10 mg | ~10 mg |
| Chain length | 3 residues | 15 residues | 7 residues |
| Relative synthesis cost | Low | High | High |
| Effect on vial price | Minimal | Substantial | Substantial |
GHK-Cu carries most of the vial's milligram mass at roughly 30 to 70 mg while BPC-157 and TB-500 sit near 10 mg each, so a larger total-milligram label mostly adds the cheapest three-residue component and barely changes the cost of the two costly ones.
Roughly sixty to just under two hundred US dollars per vial captures most of what the market displays, though the shape of that distribution matters more than its endpoints. The lower band reflects thin documentation and overseas drop-ship fulfillment, while the upper band accompanies batch-specific testing and cold-chain handling. Multi-vial pricing sits below both, so any single-unit figure overstates what active buyers actually pay.
Most listings fall between roughly $60 and just under $200 per vial, with a 30-to-70 mg GHK-Cu step commonly adding $30 to $60, and effective per-vial cost dropping 15 to 30 percent at five- or ten-vial quantities.
Per-milligram cost is the standard method for comparing single-peptide listings, and applied unmodified to a blend it produces a figure that is not just imprecise but actively misleading. The naive calculation treats a milligram of the cheapest component as equal to a milligram of the most expensive, which is exactly the substitution the pricing structure of these blends exploits. A weighted read against each component's standalone rate is the honest alternative.
| Reading method | What it measures | Where it fails |
|---|---|---|
| Naive per-milligram | Vial price divided by total milligrams | Treats cheap GHK-Cu mass as equal to the costly components |
| Weighted per-milligram | Each component against its standalone market rate | Requires reliable standalone prices to compute |
| Per-dose | Real cost across usable doses after residue | Inherits any error in unverified label content |
A naive per-milligram figure divides vial price by total milligrams, so a 70 mg GHK-Cu vial with 10 mg each of BPC-157 and TB-500 at $150 reads as about $1.67 per milligram, a number that collapses once each component is priced against its own standalone rate.
A two-to-threefold gap between the cheapest and dearest listing of a nominally identical product is normal here, and much of it is not product difference at all. A small number of contract synthesis facilities supply a large, fragmented reseller layer, so two listings at very different prices are frequently the same material out of the same reactor with different labels applied downstream. Where genuine cost difference exists, it concentrates in a handful of factors.
A two-to-threefold price gap between nominally identical listings is normal, and once purity grade, per-batch testing, and fulfillment are accounted for, a substantial residue of the spread traces to positioning rather than to anything in the vial.
Assembling the same three peptides individually is usually the cheaper transaction on paper, and the gap is smaller than either side of the argument tends to claim. What the blend sells is not a materials discount but a reduction in transactions: one vial, one reconstitution, one shipment, and no arithmetic to reconcile three separate concentrations. The real tradeoff is the fixed ratio, which commits its user to the manufacturer's proportions permanently.
| Dimension | Premixed blend | Separate sourcing |
|---|---|---|
| Materials cost | Near the middle of the observed band | Usually slightly lower |
| Ratio flexibility | Locked to the manufacturer's proportions | Each component adjustable |
| Transactions | One vial, one reconstitution, one shipment | Three of each |
| Waste on non-completion | All three discarded on one shelf-life clock | Each vial its own clock and dead volume |
Sourcing GHK-Cu, BPC-157, and TB-500 separately usually costs slightly less and preserves ratio flexibility, while the blend buys simplicity at a small premium, so the fixed ratio rather than the price is what separates the two paths.
A vial of lyophilized powder is not a usable item on arrival, and the gap between the quoted price and the total outlay is routinely underestimated. Reconstitution supplies, shipping, and minimum-order thresholds each add to the sticker before a single dose is drawn. International orders introduce a further layer of cost that is difficult to forecast.
Bacteriostatic water at $5 to $15, syringes at $10 to $25 per hundred, shipping at $10 to $30, and free-shipping floors near $150 to $200 push the true cost of a single usable vial well above its quoted price.
Single-vial pricing is the wrong unit for understanding this market, because nothing about these compounds is used in single-vial quantities. Protocol descriptions circulating in the research chemical space commonly run four to twelve weeks at daily or near-daily administration, which consumes a mid-range vial in one to three weeks. The durations that drive this arithmetic come from vendor literature rather than controlled human trials.
A four-to-twelve-week protocol at daily dosing consumes roughly three to eight vials, so a $120 vial produces a materials cost near $720 for a six-vial run, though the protocol lengths driving that figure come from vendor literature rather than controlled human trials.
Testing is the one line item in this market where a price difference maps to something real, and it is also the one most easily faked. A certificate of analysis attests only that a specific batch was assayed and found to contain a stated compound at a stated purity, which is a narrower claim than most readers take it for. For a blend, that certificate carries a demand a single-peptide product does not.
Per-batch HPLC and mass-spectrometry testing costs in the low hundreds of dollars and, for a blend, is only meaningful when the certificate resolves all three components separately against a batch number that matches the vial in hand.
Every commercial condition in this market descends from a single regulatory fact: no version of this blend is an approved drug, and it is sold under research-use-only labelling that positions it as a laboratory reagent rather than a therapeutic. That label is what permits the transaction to occur at all, and it disclaims the seller's responsibility for human use without conferring any protection on the buyer. Taken individually, the three components sit in meaningfully different regulatory positions.
No version of the blend is an FDA-approved drug; it is sold under research-use-only labelling, and BPC-157 in particular remains unapproved, is absent from the 503A compounding bulks list, and has no lawful compounding pathway at present.
The intuition that price tracks quality is weaker here than in almost any adjacent market, for structural rather than incidental reasons. Because a fragmented reseller layer draws on a concentrated synthesis base, margin moves freely while the underlying material frequently does not, and independent testing initiatives that have assayed samples from this segment have repeatedly found content deviating from label claims across the price spectrum, including at the expensive end. The failure modes that matter most are invisible to price by construction.
Independent assays of this segment have repeatedly found contents deviating from label claims across the entire price range, including at the expensive end, so only batch-specific third-party analysis resolving all three components, not price, indicates what is actually in the vial.
Educational use only. This article describes what the published scientific and clinical literature reports about GLOW blend. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
